Straits Times Index
3,348.87 +12.28 (+0.37%) S&P 500
5,269.55 -7.96 (-0.15%) Dow
38,440.90 -245.42 (-0.63%) Nasdaq
16,791.02 +56.01 (+0.33%) Bitcoin USD
69,300.17 +1,231.30 (+1.81%) CMC Crypto 200
1,489.06 +21.12 (+1.44%)
LLY Jan 2025 710.000 put
- Zacks
The Zacks Analyst Blog Highlights Eli Lilly, T-Mobile US, BHP, American International and Exelon
Eli Lilly, T-Mobile US, BHP, American International and Exelon are part of the Zacks Analyst Blog.
- PR Newswire
Updated Data from the Phase 1/2 Study of Olomorasib in KRAS G12C-Mutant Advanced Solid Tumors Presented at the 2024 ASCO® Annual Meeting
Eli Lilly and Company (NYSE: LLY) today announced updated data from the Phase 1/2 clinical trial evaluating olomorasib as a monotherapy in patients with KRAS G12C-mutant advanced solid tumors and in combination with Merck's anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in patients with KRAS G12C-mutant advanced non-small cell lung cancer (NSCLC). Olomorasib is an investigational, oral, potent, and highly selective second-generation inhibitor of the KRAS G12C protein. These data will be shared in o
- Zacks
Top Research Reports for Eli Lilly, T-Mobile & BHP
Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), T-Mobile US, Inc. (TMUS) and BHP Group Limited (BHP).
